Document Detail


Evaluation of menogaril in patients with metastatic sarcomas and no prior chemotherapy exposure.
MedLine Citation:
PMID:  2529759     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Menogaril, an anthracycline analog of nogalamycin, is reported to have greater cytotoxicity against certain malignant cell lines and less cardiotoxicity in rabbits than doxorubicin. To evaluate the possible therapeutic benefit of this drug, we studied menogaril in 21 patients with metastatic sarcomas who had received no prior chemotherapy. Menogaril was administered intravenously over 1 h every 3-4 weeks at a dose of 200 mg/m2 in 500 ml of 5% dextrose in water. One patient experienced a partial regression of pulmonary metastases from malignant fibrous histiocytoma of bone (response rate of 5% with 95% confidence interval of 0.1-23.8%). Two additional patients experienced minor reductions in tumor size. The remaining 18 patients had no improvement from menogaril. The median time to disease progression was 7 weeks in all patients treated. Toxicity was acceptable, consisting primarily of leukopenia with 12 patients (57%) and 19 patients (90%) developing nadir leukocyte counts less than 2000 and 3000/microL, respectively. Cardiac toxicity was not encountered; however, only seven patients received greater than or equal to 3 cycles of menogaril. We conclude that menogaril does not appear to be useful at this dose and schedule in the treatment of metastatic sarcomas despite the use of near maximal doses in patients with no prior chemotherapy exposure.
Authors:
J C Buckner; J H Edmonson; J N Ingle; D J Schaid
Related Documents :
361229 - Clinical trial of rubidazone in advanced squamous cell carcinoma of the lung and adenoc...
9157079 - Phase ii study of mitonafide in non-small cell lung cancer (nsclc).
16316459 - First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic ...
1312909 - Phase ii study of acnu as second-line treatment in small-cell lung cancer. eortc lung c...
1433369 - Antitumor activity and clinical pharmacology of sulofenur in ovarian cancer.
6451289 - An abbreviated phase ii trial of thalicarpine.
23359779 - Proton therapy for hepatocellular carcinoma.
11090079 - Evaluation of apaf-1 and procaspases-2, -3, -7, -8, and -9 as potential prognostic mark...
15384089 - Predictors of long-term survival in pn3 gastric cancer patients.
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  American journal of clinical oncology     Volume:  12     ISSN:  0277-3732     ISO Abbreviation:  Am. J. Clin. Oncol.     Publication Date:  1989 Oct 
Date Detail:
Created Date:  1989-11-01     Completed Date:  1989-11-01     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  8207754     Medline TA:  Am J Clin Oncol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  384-6     Citation Subset:  IM    
Affiliation:
Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antineoplastic Agents / adverse effects,  therapeutic use*
Daunorubicin / analogs & derivatives*
Drug Evaluation
Female
Humans
Leukopenia / chemically induced
Male
Menogaril
Middle Aged
Nogalamycin / adverse effects,  analogs & derivatives,  therapeutic use*
Sarcoma / drug therapy*,  secondary
Grant Support
ID/Acronym/Agency:
CA-15083/CA/NCI NIH HHS; CM-57733B/CM/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 1404-15-5/Nogalamycin; 20830-81-3/Daunorubicin; 71628-96-1/Menogaril

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Influence of temporal smoothing on quantitation of left ventricular function by gated blood pool sci...
Next Document:  Lipocortin-1 immunoreactivity in the normal human central nervous system and lesions with astrocytos...